drugset / Trial / NCT03725566
JY028 Single Vitreous Injection in a Phase 1 Clinical Trial in nAMD Patients
SequentialOpen-labelOther
Summary
Phase I clinical trial on safety, tolerance, pharmacokinetics (PK) and pharmacodynamics of recombinant human anti-VEGF monoclonal antibody injection in patients with neovascular (wet) age-related macular degeneration
Timeline
- Start
- 2018-05-22
- Primary completion
- 2020-05-01
- Completion
- 2020-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JY028 | Monoclonal antibody | 0.625 mg | Intravitreal |
| Subject | JY028 | Monoclonal antibody | 1.25 mg | Intravitreal |
| Subject | JY028 | Monoclonal antibody | 2 mg | Intravitreal |
| Subject | JY028 | Monoclonal antibody | 2.5 mg | Intravitreal |